Lilly Oncology Sponsors Thyroid Cancer Testing Program through NeoGenomics.
NeoGenomics is pleased to partner with Lilly Oncology on the Thyroid Cancer Testing Program to provide access to molecular testing for appropriate advanced thyroid cancer patients, including:
- Advanced or metastatic medullary thyroid cancer (MTC) patients 12 years of age and older who require systemic therapy
- Advanced or metastatic non-medullary thyroid cancer (non-MTC) patients 12 years of age and older who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
Eligible patients may receive either test, regardless of test results or treatment decision
- One (1) NGS Thyroid Profile test (for MTC)
- One (1) NGS Thyroid Profile plus RET FISH test (for non-MTC)
Enroll your thyroid cancer patients today for a molecular test at no cost!
- Fill out the Thyroid Cancer Testing Program Test Request Form
- Submit patient tissue sample to NeoGenomics along with the completed Test Request Form
- Receive test results through your preferred method of delivery within 14 days of receipt of the patient sample.
No patient, health care program, or beneficiary shall be billed for this genomic test through the Thyroid Cancer Testing Program. For more information please review our linked Resources for full details.
Notice to New York State clients: The Thyroid Cancer Testing Program is NOT available to New York State patients and facilities as the aforementioned NGS tests have not been approved by the New York State Department of Health.
Patients, please consult your medical care team to discuss whether you are a candidate for testing.
Frequently Asked Questions for Healthcare Professionals
The Thyroid Cancer Testing Program is a Lilly Oncology sponsored program offering molecular testing at no cost to appropriate thyroid cancer patients. Lilly will cover the cost of the test regardless of the test results and treatment decision.
Any patient 12 years of age and older with advanced or metastatic medullary thyroid cancer (“MTC”) who requires systemic therapy or with advanced or metastatic non-medullary thyroid cancer (“non-MTC”) who requires systemic therapy and who is radioactive iodine-refractory (if radioactive iodine is appropriate) is eligible to enroll in the Thyroid Cancer Testing Program to receive genomic cancer testing at no cost.
Patients who have not previously undergone biopsy may still enroll in the program, but are responsible for working with their physician to extract a viable tumor specimen and cover any associated expenses.
All eligible patients who enroll in the Thyroid Cancer Testing Program will receive either one (1) NGS Thyroid Profile test (for MTC patients) or one (1) NGS Thyroid Profile plus RET FISH test (for non-MTC patients).
NGS Thyroid Profile for MTC: AKT1, ALK, ARID1A, ATM, BRAF, CDKN2A, CTNNB1, ERBB2, ERBB4, HRAS, KRAS, MEN1, MET, NF1, NF2, NRAS, PIK3CA, PTEN, RET, SMAD4, SMO, SRC, TERT Promoter, TP53, TSC1, and TSC2
NGS Thyroid Profile plus RET FISH for non-MTC: AKT1, ALK, ARID1A, ATM, BRAF, CDKN2A, CTNNB1, ERBB2, ERBB4, HRAS, KRAS, MEN1, MET, NF1, NF2, NRAS, PIK3CA, PTEN, RET, RET FISH, SMAD4, SMO, SRC, TERT Promoter, TP53, TSC1, and TSC2.
NeoGenomics offers NGS testing for thyroid cancer on formalin-fixed paraffin-embedded (FFPE) tissue. Paraffin block is preferred. Please use 10% buffered formalin fixative. Do not use zinc fixative.
Results will be sent to the ordering physician’s office or laboratory within 14 days after sample is received.
Any patient meeting the eligibility criteria can enroll in the program regardless of insurance coverage.
There will be no cost for patients, healthcare providers or insurance companies for the NGS or FISH tests.
No bill will be sent to patients, healthcare providers or insurance companies who participate through this program. If a bill is received in error, please disregard or contact NeoGenomics at 866.776.5907, option 3.
Contact NeoGenomics at 866.776.5907, option 3 for supplies.
We are looking forward to working with you! Please contact NeoGenomics Client Services at 866.776.5907, option 3 to set up your new account.
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients